Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | BCHE | P06276 | 7/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17386027 | 1.00 | CYP4F2 (0.59) | CYP4F2CYP4A11MAOBMEN1KMT2A | |
| SCHEMBL321092 | 0.87 | MAOB (0.62) | CYP4F2CYP4A11MAOBMEN1KMT2A | |
| SCHEMBL9125550 | 0.86 | ALOX5 (0.61) | MAOBMEN1KMT2AMAPTRAB9A | |
| SCHEMBL21583868 | 0.85 | TAAR1 (0.65) | CYP4F2CYP4A11MAOBKMT2ABCHE | |
| SCHEMBL2747426 | 0.85 | TAAR1 (0.65) | CYP4F2CYP4A11MAOBKMT2ABCHE | |
| SCHEMBL30211131 | 0.85 | TAAR1 (0.65) | CYP4F2CYP4A11MAOBKMT2ABCHE | |
| SCHEMBL2747423 | 0.85 | TAAR1 (0.65) | CYP4F2CYP4A11MAOBKMT2ABCHE | |
| SCHEMBL24645960 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11MAOBMEN1KMT2A | |
| SCHEMBL9845668 | 0.84 | CYP4F2 (0.60) | CYP4F2CYP4A11MAOBMEN1KMT2A | |
| SCHEMBL28969202 | 0.84 | CYP4F2 (0.56) | CYP4F2CYP4A11MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115867536-A | GPR40 agonists | 卡尔优普公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-108017603-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2021-07-23 | — | — | CN | disclosed |
| CN-107428721-B | Benzopiperidine derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-2963027-B1 | TRICYCLIC COMPOUND AND USE THEREOF | TIUMBIO CO LTD (KR) | 2018-12-26 | — | — | EP | disclosed |
| CN-105209448-B | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2018-09-14 | — | — | CN | disclosed |
| CN-108017603-A | Tricyclic compounds and uses thereof | 株式会社蒂奥姆生物 | 2018-05-11 | — | — | CN | disclosed |
| US-9643946-B2 | Tricyclic compound and use thereof | SK CHEMICALS CO., LTD. (KR) | 2017-05-09 | — | — | US | disclosed |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK CHEMICALS CO., LTD. (KR) | 2016-01-14 | — | — | US | disclosed |
| EP-2963027-A1 | TRICYCLIC COMPOUND AND USE THEREOF | SK Chemicals Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | disclosed |
| US-4933475-A | ANALGESICS, ANTIDIARREALS, ANTIEMETICS | PFIZER, INC. (US) | 1990-06-12 | — | — | US | disclosed |
| US-4835192-A | Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor | PFIZER INC. (US) | 1989-05-30 | — | — | US | disclosed |
| US-4739079-A | ANALGESICS, ANTIDIARRHEA, ANTIEMETIC AGENTS | PFIZER INC. (US) | 1988-04-19 | — | — | US | disclosed |
| US-4593131-A | Pharmacologically active 4-[2-hydroxy-4-(substituted)phenyl]naphthalen-2(1H)-ones and 2-ols, derivatives thereof and intermediates therefor | PFIZER INC. (US) | 1986-06-03 | — | — | US | disclosed |
| US-4486609-A | ANALGESICS | PFIZER INC. (US) | 1984-12-04 | — | — | US | disclosed |
| EP-0049953-B1 | 4-(SUBSTITUTED PHENYL)-NAPHTHALEN-2(1H)-ONES AND 2-OLS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4331602-A | CNS AGENTS, ANTIEMETICS, ANTIDIARRHEA | PFIZER INC. (US) | 1982-05-25 | — | — | US | disclosed |
| EP-0049953-A2 | 4-(Substituted phenyl)-naphthalen-2(1H)-ones and 2-ols, processes for their preparation, and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-21 | — | — | EP | disclosed |
| US-4285867-A | ANTIDIARRHEA AGENTS, ANTIEMETICS, ANALGESICS | PFIZER INC. (US) | 1981-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | CYP4F2 1295/4885CYP4A11 592/4885MAOB 2716/4885 |
| US-20160009677-A1 | TRICYCLIC COMPOUND AND USE THEREOF | GPR65, GPR119, GPR35 | CYP4F2 958/4885CYP4A11 159/4885MAOB 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.